Press release
Investigation announced for Long-Term Investors in shares of Acelyrin, Inc. (NASDAQ: SLRN)
An investigation on behalf of current long term investors in Acelyrin, Inc. (NASDAQ: SLRN) shares.
Investors who are current long term investors in Acelyrin, Inc. (NASDAQ: SLRN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SLRN stocks follows a lawsuit filed against Acelyrin, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SLRN stocks, concerns whether certain Acelyrin, Inc. officers and directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that izokibep was less effective in treating HS than Defendants had led investors to believe, that accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects, that as a result, Acelyrin also overstated the Company's business prospects post-IPO, and thatas a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Acelyrin, Inc. (NASDAQ: SLRN) here
News-ID: 3494998 • Views: …
More Releases from Shareholders Foundation, Inc.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) Investor Alert: Deadline in Lawsuit …
A deadline is coming up on May 4, 2026 in the lawsuit filed for certain investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) over alleged securities laws violations by Aquestive Therapeutics, Inc.
Investors who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) have certain options and there are strict and short deadlines running. Deadline: May 4, 2026. NASDAQ: AQST stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation Alert: Long-Term Investors who lost money with shares of Skye Bios …
An investigation was announced on behalf of current long-term investors in shares of Skye Bioscience, Inc. (NASDAQ: SKYE) concerning potential breaches of fiduciary duties by certain directors and officers of Skye Bioscience, Inc..
Investors who are current long term investors in Skye Bioscience, Inc. (NASDAQ: SKYE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for…
Lawsuit filed for Investors who lost money with shares of Gossamer Bio, Inc. (NA …
An investor, who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), filed a lawsuit in the U.S. District Court for the Southern District of California over alleged violations of Federal Securities Laws by Gossamer Bio, Inc. in connection with certain allegedly false and misleading statements made between June 16, 2025, and February 20, 2026.
Investors who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS) have certain options and for certain investors…
Eos Energy Enterprises, Inc. (NASDAQ: EOSE) Investor Alert: Deadline in Lawsuit …
A deadline is coming up on May 5, 2026H in the lawsuit filed for certain investors of Eos Energy Enterprises, Inc. (NASDAQ: EOSE) over alleged securities laws violations by Eos Energy Enterprises, Inc. (NASDAQ: EOSE).
Investors who purchased shares of Eos Energy Enterprises, Inc. (NASDAQ: EOSE) have certain options and there are strict and short deadlines running. Deadline: May 5, 2026. Eos Energy Enterprises, Inc. (NASDAQ: EOSE) stockholders should contact the…
More Releases for Acelyrin
Uveitis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight …
DelveInsight's "Uveitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Uveitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Uveitis Market Forecast
https://www.delveinsight.com/sample-request/uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Uveitis…
Thyroid Eye Disease Market Top Players - Horizon Therapeutics, Viridian Therapeu …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Thyroid Eye Disease Market - (By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Thyroid Eye Disease Market is valued at US$ 2.15 billion in 2023, and it is expected to reach US$…
Hidradenitis Suppurativa Treatment Market 2034: FDA Approvals, Clinical trials, …
(Albany, USA) DelveInsight's "Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hidradenitis Suppurativa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hidradenitis Suppurativa Market Forecast
https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the…
Deadline on Jan. 16th coming up in Lawsuit filed for Investors in shares of Acel …
A deadline is coming up on January 16, 2024 in the lawsuit filed for certain investors of Acelyrin, Inc. (NASDAQ: SLRN) over alleged securities laws violations by Acelyrin, Inc. (NASDAQ: SLRN).
Investors who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and there are strict and short deadlines running. Deadline: January 16, 2024. NASDAQ: SLRN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According…
Lawsuit filed for Investors who lost money with shares of Acelyrin, Inc. (NASDAQ …
An investor, who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN), filed a lawsuit over alleged violations of Federal Securities Laws by Acelyrin, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 16, 2024. NASDAQ: SLRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investigation announced for Investors in shares of Acelyrin, Inc. (NASDAQ: SLRN) …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Acelyrin, Inc.
Investors who purchased shares of Acelyrin, Inc. (NASDAQ: SLRN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Acelyrin, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Agoura Hills, CA based…
